Biovail faces lawsuits from hedge fund and analysts it sued
This article was originally published in Scrip
Two separate complaints have been filed against Biovail by a hedge fund and an analyst firm that allege the Canadian company committed malicious prosecution in filing lawsuits against them in 2006. Biovail's case against the hedge fund was thrown out of court in New Jersey in August 2009 by a judge who said the court lacked jurisdiction.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.